Skip to main content
BioNumerik Pharmaceuticals, Inc. Home Page

Product Candidates

BioNumerik Pharmaceuticals, Inc. Feature

Preclinical Pipeline

BioNumerik has multiple other oncology research programs, including preclinical development programs in the areas of DNA methyltransferase modulators, novel platinum drugs, small molecule Bcl-2 inhibitors, novel taxane formulations, small molecule inhibitors for mitotic arrest, neuro- and nephro-toxicity protection agents, and additional karenitecin class molecules.